WallStSmart

EDAP TMS SA (EDAP)vsQuipt Home Medical Corp (QIPT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Quipt Home Medical Corp generates 258% more annual revenue ($264.97M vs $74.07M). QIPT leads profitability with a -0.0% profit margin vs -41.7%. QIPT earns a higher WallStSmart Score of 40/100 (D).

EDAP

Avoid

25

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 5.7Quality: 5.0

QIPT

Hold

40

out of 100

Grade: D

Growth: 5.3Profit: 2.5Value: 5.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EDAPUndervalued (+41.7%)

Margin of Safety

+41.7%

Fair Value

$8.41

Current Price

$4.31

$4.10 discount

UndervaluedFair: $8.41Overvalued
QIPTUndervalued (+8.7%)

Margin of Safety

+8.7%

Fair Value

$3.90

Current Price

$3.65

$0.25 discount

UndervaluedFair: $3.90Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EDAP0 strengths · Avg: 0/10

No standout strengths identified

QIPT1 strengths · Avg: 8.0/10
Price/BookValuation
1.6x8/10

Reasonable price relative to book value

Areas to Watch

EDAP4 concerns · Avg: 2.8/10
Price/BookValuation
8.3x4/10

Trading at 8.3x book value

Market CapQuality
$156.30M3/10

Smaller company, higher risk/reward

PEG RatioValuation
90.472/10

Expensive relative to growth rate

Return on EquityProfitability
-124.0%2/10

ROE of -124.0% — below average capital efficiency

QIPT4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
0.3%4/10

0.3% revenue growth

Market CapQuality
$162.30M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Return on EquityProfitability
-0.1%2/10

ROE of -0.1% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : EDAP

Revenue growth of 13.9% demonstrates continued momentum.

Bull Case : QIPT

The strongest argument for QIPT centers on Price/Book.

Bear Case : EDAP

The primary concerns for EDAP are Price/Book, Market Cap, PEG Ratio.

Bear Case : QIPT

The primary concerns for QIPT are Revenue Growth, Market Cap, Operating Margin.

Key Dynamics to Monitor

QIPT carries more volatility with a beta of 0.49 — expect wider price swings.

EDAP is growing revenue faster at 13.9% — sustainability is the question.

QIPT generates stronger free cash flow (7M), providing more financial flexibility.

Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

QIPT scores higher overall (40/100 vs 25/100). EDAP offers better value entry with a 41.7% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

EDAP TMS SA

HEALTHCARE · MEDICAL DISTRIBUTION · USA

EDAP TMS SA, develops, produces, markets, distributes and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States and internationally. The company is headquartered in Lyon, France.

Quipt Home Medical Corp

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Quipt Home Medical Corp. The company is headquartered in Wilder, Kentucky.

Want to dig deeper into these stocks?